nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—DCLK3—urine—urinary bladder cancer	0.0137	0.039	CbGeAlD
Ruxolitinib—Myelosuppression—Mitomycin—urinary bladder cancer	0.00925	0.054	CcSEcCtD
Ruxolitinib—PRKG2—prostate gland—urinary bladder cancer	0.00578	0.0165	CbGeAlD
Ruxolitinib—PRKCE—prostate gland—urinary bladder cancer	0.0054	0.0154	CbGeAlD
Ruxolitinib—RPS6KA6—prostate gland—urinary bladder cancer	0.00518	0.0148	CbGeAlD
Ruxolitinib—PLK1—prostate gland—urinary bladder cancer	0.00518	0.0148	CbGeAlD
Ruxolitinib—Myelosuppression—Thiotepa—urinary bladder cancer	0.00465	0.0272	CcSEcCtD
Ruxolitinib—PLK3—prostate gland—urinary bladder cancer	0.00433	0.0123	CbGeAlD
Ruxolitinib—PRKG2—smooth muscle tissue—urinary bladder cancer	0.00409	0.0117	CbGeAlD
Ruxolitinib—CAMK1—prostate gland—urinary bladder cancer	0.00405	0.0115	CbGeAlD
Ruxolitinib—PRKG2—renal system—urinary bladder cancer	0.00394	0.0112	CbGeAlD
Ruxolitinib—MARK2—prostate gland—urinary bladder cancer	0.00393	0.0112	CbGeAlD
Ruxolitinib—Myelosuppression—Fluorouracil—urinary bladder cancer	0.00385	0.0225	CcSEcCtD
Ruxolitinib—Myelosuppression—Cisplatin—urinary bladder cancer	0.00365	0.0213	CcSEcCtD
Ruxolitinib—TAOK2—prostate gland—urinary bladder cancer	0.00364	0.0104	CbGeAlD
Ruxolitinib—Urinary tract infection—Valrubicin—urinary bladder cancer	0.00342	0.02	CcSEcCtD
Ruxolitinib—CAMK1—seminal vesicle—urinary bladder cancer	0.00342	0.00975	CbGeAlD
Ruxolitinib—Haematuria—Valrubicin—urinary bladder cancer	0.00336	0.0196	CcSEcCtD
Ruxolitinib—Myelosuppression—Etoposide—urinary bladder cancer	0.00334	0.0195	CcSEcCtD
Ruxolitinib—JAK3—prostate gland—urinary bladder cancer	0.00334	0.00952	CbGeAlD
Ruxolitinib—JAK1—prostate gland—urinary bladder cancer	0.00332	0.00946	CbGeAlD
Ruxolitinib—DCLK1—prostate gland—urinary bladder cancer	0.00332	0.00946	CbGeAlD
Ruxolitinib—CAMK1D—prostate gland—urinary bladder cancer	0.00324	0.00923	CbGeAlD
Ruxolitinib—PHKG2—prostate gland—urinary bladder cancer	0.00322	0.00918	CbGeAlD
Ruxolitinib—DAPK2—prostate gland—urinary bladder cancer	0.00317	0.00902	CbGeAlD
Ruxolitinib—STK16—prostate gland—urinary bladder cancer	0.00312	0.00888	CbGeAlD
Ruxolitinib—HIPK2—prostate gland—urinary bladder cancer	0.0031	0.00883	CbGeAlD
Ruxolitinib—DAPK3—prostate gland—urinary bladder cancer	0.00298	0.00848	CbGeAlD
Ruxolitinib—CLK2—prostate gland—urinary bladder cancer	0.00295	0.0084	CbGeAlD
Ruxolitinib—PRKCE—female reproductive system—urinary bladder cancer	0.00295	0.00839	CbGeAlD
Ruxolitinib—PLK3—urethra—urinary bladder cancer	0.0029	0.00825	CbGeAlD
Ruxolitinib—ROCK1—prostate gland—urinary bladder cancer	0.00286	0.00814	CbGeAlD
Ruxolitinib—RPS6KA6—female reproductive system—urinary bladder cancer	0.00283	0.00806	CbGeAlD
Ruxolitinib—PLK1—female reproductive system—urinary bladder cancer	0.00283	0.00806	CbGeAlD
Ruxolitinib—JAK1—seminal vesicle—urinary bladder cancer	0.00281	0.008	CbGeAlD
Ruxolitinib—DYRK1A—prostate gland—urinary bladder cancer	0.00279	0.00794	CbGeAlD
Ruxolitinib—BMPR2—prostate gland—urinary bladder cancer	0.00278	0.00791	CbGeAlD
Ruxolitinib—Flatulence—Valrubicin—urinary bladder cancer	0.00271	0.0158	CcSEcCtD
Ruxolitinib—CAMK1—urethra—urinary bladder cancer	0.00271	0.00772	CbGeAlD
Ruxolitinib—DAPK2—seminal vesicle—urinary bladder cancer	0.00268	0.00763	CbGeAlD
Ruxolitinib—Pancytopenia—Mitomycin—urinary bladder cancer	0.00258	0.0151	CcSEcCtD
Ruxolitinib—Anaemia—Valrubicin—urinary bladder cancer	0.00254	0.0149	CcSEcCtD
Ruxolitinib—CLK2—seminal vesicle—urinary bladder cancer	0.00249	0.00711	CbGeAlD
Ruxolitinib—BMP2K—prostate gland—urinary bladder cancer	0.00249	0.00708	CbGeAlD
Ruxolitinib—CAMK2G—prostate gland—urinary bladder cancer	0.00249	0.00708	CbGeAlD
Ruxolitinib—LRRK2—prostate gland—urinary bladder cancer	0.00246	0.00702	CbGeAlD
Ruxolitinib—JAK1—epithelium—urinary bladder cancer	0.00244	0.00695	CbGeAlD
Ruxolitinib—TAOK2—urethra—urinary bladder cancer	0.00243	0.00693	CbGeAlD
Ruxolitinib—DCLK3—vagina—urinary bladder cancer	0.00243	0.00691	CbGeAlD
Ruxolitinib—PLK3—female reproductive system—urinary bladder cancer	0.00236	0.00673	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—urinary bladder cancer	0.00235	0.0067	CbGeAlD
Ruxolitinib—LTK—female reproductive system—urinary bladder cancer	0.00228	0.0065	CbGeAlD
Ruxolitinib—JAK1—renal system—urinary bladder cancer	0.00226	0.00645	CbGeAlD
Ruxolitinib—MAP3K2—prostate gland—urinary bladder cancer	0.00226	0.00643	CbGeAlD
Ruxolitinib—NUAK2—seminal vesicle—urinary bladder cancer	0.00224	0.00639	CbGeAlD
Ruxolitinib—MAP3K7—prostate gland—urinary bladder cancer	0.00224	0.00637	CbGeAlD
Ruxolitinib—JAK1—urethra—urinary bladder cancer	0.00222	0.00633	CbGeAlD
Ruxolitinib—DCLK1—urethra—urinary bladder cancer	0.00222	0.00633	CbGeAlD
Ruxolitinib—CAMK1—female reproductive system—urinary bladder cancer	0.00221	0.00629	CbGeAlD
Ruxolitinib—TYK2—prostate gland—urinary bladder cancer	0.0022	0.00625	CbGeAlD
Ruxolitinib—CAMK1D—urethra—urinary bladder cancer	0.00217	0.00618	CbGeAlD
Ruxolitinib—IRAK1—prostate gland—urinary bladder cancer	0.00217	0.00617	CbGeAlD
Ruxolitinib—MKNK2—prostate gland—urinary bladder cancer	0.00217	0.00617	CbGeAlD
Ruxolitinib—MARK2—female reproductive system—urinary bladder cancer	0.00214	0.00611	CbGeAlD
Ruxolitinib—PLK3—vagina—urinary bladder cancer	0.00214	0.00609	CbGeAlD
Ruxolitinib—DAPK2—urethra—urinary bladder cancer	0.00212	0.00604	CbGeAlD
Ruxolitinib—RET—prostate gland—urinary bladder cancer	0.00211	0.00602	CbGeAlD
Ruxolitinib—HIPK2—renal system—urinary bladder cancer	0.00211	0.00602	CbGeAlD
Ruxolitinib—DAPK3—smooth muscle tissue—urinary bladder cancer	0.00211	0.00601	CbGeAlD
Ruxolitinib—ROCK1—epithelium—urinary bladder cancer	0.0021	0.00598	CbGeAlD
Ruxolitinib—LRRK2—seminal vesicle—urinary bladder cancer	0.00208	0.00593	CbGeAlD
Ruxolitinib—Infection—Carboplatin—urinary bladder cancer	0.00207	0.0121	CcSEcCtD
Ruxolitinib—DAPK3—renal system—urinary bladder cancer	0.00203	0.00578	CbGeAlD
Ruxolitinib—ROCK1—smooth muscle tissue—urinary bladder cancer	0.00202	0.00577	CbGeAlD
Ruxolitinib—CLK2—renal system—urinary bladder cancer	0.00201	0.00573	CbGeAlD
Ruxolitinib—CAMK1—vagina—urinary bladder cancer	0.002	0.00569	CbGeAlD
Ruxolitinib—JAK2—prostate gland—urinary bladder cancer	0.002	0.00569	CbGeAlD
Ruxolitinib—DAPK3—urethra—urinary bladder cancer	0.00199	0.00568	CbGeAlD
Ruxolitinib—CLK2—urethra—urinary bladder cancer	0.00197	0.00563	CbGeAlD
Ruxolitinib—BMPR2—smooth muscle tissue—urinary bladder cancer	0.00197	0.0056	CbGeAlD
Ruxolitinib—ROCK1—renal system—urinary bladder cancer	0.00195	0.00555	CbGeAlD
Ruxolitinib—MAP3K3—prostate gland—urinary bladder cancer	0.00192	0.00548	CbGeAlD
Ruxolitinib—Bone pain—Gemcitabine—urinary bladder cancer	0.00192	0.0112	CcSEcCtD
Ruxolitinib—DYRK1A—renal system—urinary bladder cancer	0.0019	0.00541	CbGeAlD
Ruxolitinib—BMPR2—renal system—urinary bladder cancer	0.00189	0.00539	CbGeAlD
Ruxolitinib—MAP3K7—seminal vesicle—urinary bladder cancer	0.00189	0.00539	CbGeAlD
Ruxolitinib—Myelosuppression—Epirubicin—urinary bladder cancer	0.00187	0.0109	CcSEcCtD
Ruxolitinib—BMPR2—urethra—urinary bladder cancer	0.00186	0.0053	CbGeAlD
Ruxolitinib—TYK2—seminal vesicle—urinary bladder cancer	0.00186	0.00529	CbGeAlD
Ruxolitinib—MKNK2—seminal vesicle—urinary bladder cancer	0.00183	0.00522	CbGeAlD
Ruxolitinib—JAK3—female reproductive system—urinary bladder cancer	0.00182	0.0052	CbGeAlD
Ruxolitinib—JAK1—female reproductive system—urinary bladder cancer	0.00181	0.00516	CbGeAlD
Ruxolitinib—PLK4—female reproductive system—urinary bladder cancer	0.0018	0.00513	CbGeAlD
Ruxolitinib—TAOK2—vagina—urinary bladder cancer	0.00179	0.00511	CbGeAlD
Ruxolitinib—Body temperature increased—Valrubicin—urinary bladder cancer	0.00178	0.0104	CcSEcCtD
Ruxolitinib—PHKG2—female reproductive system—urinary bladder cancer	0.00176	0.00501	CbGeAlD
Ruxolitinib—TAOK3—prostate gland—urinary bladder cancer	0.00175	0.005	CbGeAlD
Ruxolitinib—Anaemia—Mitomycin—urinary bladder cancer	0.00175	0.0102	CcSEcCtD
Ruxolitinib—Myelosuppression—Doxorubicin—urinary bladder cancer	0.00173	0.0101	CcSEcCtD
Ruxolitinib—PRKCE—lymph node—urinary bladder cancer	0.00172	0.00491	CbGeAlD
Ruxolitinib—STK16—female reproductive system—urinary bladder cancer	0.0017	0.00485	CbGeAlD
Ruxolitinib—HIPK2—female reproductive system—urinary bladder cancer	0.00169	0.00482	CbGeAlD
Ruxolitinib—JAK2—seminal vesicle—urinary bladder cancer	0.00169	0.00481	CbGeAlD
Ruxolitinib—LRRK2—renal system—urinary bladder cancer	0.00168	0.00478	CbGeAlD
Ruxolitinib—CAMK2G—urethra—urinary bladder cancer	0.00166	0.00474	CbGeAlD
Ruxolitinib—MAP3K19—female reproductive system—urinary bladder cancer	0.00166	0.00472	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—urinary bladder cancer	0.00166	0.00472	CbGeAlD
Ruxolitinib—PLK1—lymph node—urinary bladder cancer	0.00166	0.00472	CbGeAlD
Ruxolitinib—LRRK2—urethra—urinary bladder cancer	0.00165	0.0047	CbGeAlD
Ruxolitinib—Body temperature increased—Carboplatin—urinary bladder cancer	0.00164	0.0096	CcSEcCtD
Ruxolitinib—JAK1—vagina—urinary bladder cancer	0.00164	0.00467	CbGeAlD
Ruxolitinib—DCLK1—vagina—urinary bladder cancer	0.00164	0.00467	CbGeAlD
Ruxolitinib—MAP3K3—seminal vesicle—urinary bladder cancer	0.00163	0.00464	CbGeAlD
Ruxolitinib—DAPK3—female reproductive system—urinary bladder cancer	0.00163	0.00463	CbGeAlD
Ruxolitinib—Asthenia—Valrubicin—urinary bladder cancer	0.00161	0.00941	CcSEcCtD
Ruxolitinib—CLK2—female reproductive system—urinary bladder cancer	0.00161	0.00459	CbGeAlD
Ruxolitinib—CAMK1D—vagina—urinary bladder cancer	0.0016	0.00456	CbGeAlD
Ruxolitinib—MKNK2—epithelium—urinary bladder cancer	0.00159	0.00454	CbGeAlD
Ruxolitinib—Pruritus—Valrubicin—urinary bladder cancer	0.00159	0.00928	CcSEcCtD
Ruxolitinib—MAP3K7—smooth muscle tissue—urinary bladder cancer	0.00158	0.00451	CbGeAlD
Ruxolitinib—DAPK2—vagina—urinary bladder cancer	0.00156	0.00445	CbGeAlD
Ruxolitinib—ROCK1—female reproductive system—urinary bladder cancer	0.00156	0.00445	CbGeAlD
Ruxolitinib—TYK2—smooth muscle tissue—urinary bladder cancer	0.00155	0.00443	CbGeAlD
Ruxolitinib—RET—epithelium—urinary bladder cancer	0.00155	0.00442	CbGeAlD
Ruxolitinib—STK16—vagina—urinary bladder cancer	0.00154	0.00438	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—urinary bladder cancer	0.00153	0.00437	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—urinary bladder cancer	0.00153	0.00437	CbGeAlD
Ruxolitinib—DYRK1A—female reproductive system—urinary bladder cancer	0.00152	0.00434	CbGeAlD
Ruxolitinib—BMPR2—female reproductive system—urinary bladder cancer	0.00152	0.00432	CbGeAlD
Ruxolitinib—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00152	0.00885	CcSEcCtD
Ruxolitinib—MAP3K7—urethra—urinary bladder cancer	0.0015	0.00426	CbGeAlD
Ruxolitinib—TYK2—renal system—urinary bladder cancer	0.0015	0.00426	CbGeAlD
Ruxolitinib—Dizziness—Valrubicin—urinary bladder cancer	0.00149	0.00867	CcSEcCtD
Ruxolitinib—CYP3A4—urine—urinary bladder cancer	0.00149	0.00423	CbGeAlD
Ruxolitinib—TAOK3—seminal vesicle—urinary bladder cancer	0.00148	0.00423	CbGeAlD
Ruxolitinib—MKNK2—renal system—urinary bladder cancer	0.00148	0.00421	CbGeAlD
Ruxolitinib—DAPK3—vagina—urinary bladder cancer	0.00147	0.00419	CbGeAlD
Ruxolitinib—TYK2—urethra—urinary bladder cancer	0.00147	0.00419	CbGeAlD
Ruxolitinib—JAK2—epithelium—urinary bladder cancer	0.00147	0.00418	CbGeAlD
Ruxolitinib—CLK2—vagina—urinary bladder cancer	0.00146	0.00415	CbGeAlD
Ruxolitinib—MKNK2—urethra—urinary bladder cancer	0.00145	0.00413	CbGeAlD
Ruxolitinib—RET—renal system—urinary bladder cancer	0.00144	0.0041	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—urinary bladder cancer	0.00141	0.00403	CbGeAlD
Ruxolitinib—Headache—Valrubicin—urinary bladder cancer	0.00141	0.00822	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Thiotepa—urinary bladder cancer	0.0014	0.00815	CcSEcCtD
Ruxolitinib—PLK3—lymph node—urinary bladder cancer	0.00138	0.00394	CbGeAlD
Ruxolitinib—BMPR2—vagina—urinary bladder cancer	0.00137	0.00391	CbGeAlD
Ruxolitinib—JAK2—renal system—urinary bladder cancer	0.00136	0.00388	CbGeAlD
Ruxolitinib—BMP2K—female reproductive system—urinary bladder cancer	0.00136	0.00386	CbGeAlD
Ruxolitinib—CAMK2G—female reproductive system—urinary bladder cancer	0.00136	0.00386	CbGeAlD
Ruxolitinib—LRRK2—female reproductive system—urinary bladder cancer	0.00134	0.00383	CbGeAlD
Ruxolitinib—JAK2—urethra—urinary bladder cancer	0.00134	0.00381	CbGeAlD
Ruxolitinib—Fatigue—Mitomycin—urinary bladder cancer	0.00133	0.00779	CcSEcCtD
Ruxolitinib—LTK—lymph node—urinary bladder cancer	0.00133	0.0038	CbGeAlD
Ruxolitinib—NUAK2—vagina—urinary bladder cancer	0.00131	0.00373	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Fluorouracil—urinary bladder cancer	0.00131	0.00765	CcSEcCtD
Ruxolitinib—Pancytopenia—Thiotepa—urinary bladder cancer	0.0013	0.00759	CcSEcCtD
Ruxolitinib—CAMK1—lymph node—urinary bladder cancer	0.00129	0.00368	CbGeAlD
Ruxolitinib—MAP3K3—urethra—urinary bladder cancer	0.00129	0.00367	CbGeAlD
Ruxolitinib—MARK2—lymph node—urinary bladder cancer	0.00125	0.00357	CbGeAlD
Ruxolitinib—Herpes zoster—Methotrexate—urinary bladder cancer	0.00125	0.00728	CcSEcCtD
Ruxolitinib—Weight increased—Thiotepa—urinary bladder cancer	0.00125	0.00727	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Cisplatin—urinary bladder cancer	0.00124	0.00725	CcSEcCtD
Ruxolitinib—MAP3K2—female reproductive system—urinary bladder cancer	0.00123	0.00351	CbGeAlD
Ruxolitinib—CAMK2G—vagina—urinary bladder cancer	0.00123	0.0035	CbGeAlD
Ruxolitinib—BMP2K—vagina—urinary bladder cancer	0.00123	0.0035	CbGeAlD
Ruxolitinib—Body temperature increased—Mitomycin—urinary bladder cancer	0.00122	0.00714	CcSEcCtD
Ruxolitinib—Infestation NOS—Thiotepa—urinary bladder cancer	0.00122	0.00712	CcSEcCtD
Ruxolitinib—Infestation—Thiotepa—urinary bladder cancer	0.00122	0.00712	CcSEcCtD
Ruxolitinib—LRRK2—vagina—urinary bladder cancer	0.00122	0.00346	CbGeAlD
Ruxolitinib—TYK2—female reproductive system—urinary bladder cancer	0.0012	0.00341	CbGeAlD
Ruxolitinib—TAOK3—renal system—urinary bladder cancer	0.0012	0.00341	CbGeAlD
Ruxolitinib—MKNK2—female reproductive system—urinary bladder cancer	0.00118	0.00337	CbGeAlD
Ruxolitinib—IRAK1—female reproductive system—urinary bladder cancer	0.00118	0.00337	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Gemcitabine—urinary bladder cancer	0.00117	0.00686	CcSEcCtD
Ruxolitinib—TAOK3—urethra—urinary bladder cancer	0.00117	0.00335	CbGeAlD
Ruxolitinib—Herpes zoster—Epirubicin—urinary bladder cancer	0.00117	0.00681	CcSEcCtD
Ruxolitinib—Haematuria—Thiotepa—urinary bladder cancer	0.00116	0.00679	CcSEcCtD
Ruxolitinib—TAOK2—lymph node—urinary bladder cancer	0.00116	0.00331	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Thiotepa—urinary bladder cancer	0.00115	0.00674	CcSEcCtD
Ruxolitinib—Epistaxis—Thiotepa—urinary bladder cancer	0.00115	0.00672	CcSEcCtD
Ruxolitinib—Asthenia—Mitomycin—urinary bladder cancer	0.00111	0.00648	CcSEcCtD
Ruxolitinib—MAP3K7—vagina—urinary bladder cancer	0.0011	0.00314	CbGeAlD
Ruxolitinib—Haemoglobin—Thiotepa—urinary bladder cancer	0.0011	0.00643	CcSEcCtD
Ruxolitinib—Haemorrhage—Thiotepa—urinary bladder cancer	0.0011	0.0064	CcSEcCtD
Ruxolitinib—Pancytopenia—Gemcitabine—urinary bladder cancer	0.00109	0.00638	CcSEcCtD
Ruxolitinib—JAK2—female reproductive system—urinary bladder cancer	0.00109	0.00311	CbGeAlD
Ruxolitinib—TYK2—vagina—urinary bladder cancer	0.00108	0.00309	CbGeAlD
Ruxolitinib—Herpes zoster—Doxorubicin—urinary bladder cancer	0.00108	0.0063	CcSEcCtD
Ruxolitinib—Neutropenia—Gemcitabine—urinary bladder cancer	0.00108	0.00629	CcSEcCtD
Ruxolitinib—Pancytopenia—Fluorouracil—urinary bladder cancer	0.00108	0.00628	CcSEcCtD
Ruxolitinib—MKNK2—vagina—urinary bladder cancer	0.00107	0.00305	CbGeAlD
Ruxolitinib—JAK3—lymph node—urinary bladder cancer	0.00107	0.00304	CbGeAlD
Ruxolitinib—DCLK1—lymph node—urinary bladder cancer	0.00106	0.00302	CbGeAlD
Ruxolitinib—JAK1—lymph node—urinary bladder cancer	0.00106	0.00302	CbGeAlD
Ruxolitinib—PLK4—lymph node—urinary bladder cancer	0.00105	0.003	CbGeAlD
Ruxolitinib—MAP3K3—female reproductive system—urinary bladder cancer	0.00105	0.00299	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—urinary bladder cancer	0.00103	0.00295	CbGeAlD
Ruxolitinib—PHKG2—lymph node—urinary bladder cancer	0.00103	0.00293	CbGeAlD
Ruxolitinib—Dizziness—Mitomycin—urinary bladder cancer	0.00102	0.00597	CcSEcCtD
Ruxolitinib—Pancytopenia—Cisplatin—urinary bladder cancer	0.00102	0.00595	CcSEcCtD
Ruxolitinib—DAPK2—lymph node—urinary bladder cancer	0.00101	0.00288	CbGeAlD
Ruxolitinib—Infestation—Fluorouracil—urinary bladder cancer	0.00101	0.00589	CcSEcCtD
Ruxolitinib—Infestation NOS—Fluorouracil—urinary bladder cancer	0.00101	0.00589	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Etoposide—urinary bladder cancer	0.001	0.00586	CcSEcCtD
Ruxolitinib—STK16—lymph node—urinary bladder cancer	0.000995	0.00283	CbGeAlD
Ruxolitinib—HIPK2—lymph node—urinary bladder cancer	0.00099	0.00282	CbGeAlD
Ruxolitinib—JAK2—vagina—urinary bladder cancer	0.000986	0.00281	CbGeAlD
Ruxolitinib—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.000981	0.00573	CcSEcCtD
Ruxolitinib—Haematuria—Gemcitabine—urinary bladder cancer	0.000979	0.00571	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Gemcitabine—urinary bladder cancer	0.000971	0.00567	CcSEcCtD
Ruxolitinib—Headache—Mitomycin—urinary bladder cancer	0.00097	0.00566	CcSEcCtD
Ruxolitinib—TAOK3—female reproductive system—urinary bladder cancer	0.000958	0.00273	CbGeAlD
Ruxolitinib—Malnutrition—Thiotepa—urinary bladder cancer	0.000954	0.00557	CcSEcCtD
Ruxolitinib—Epistaxis—Fluorouracil—urinary bladder cancer	0.000952	0.00556	CcSEcCtD
Ruxolitinib—DAPK3—lymph node—urinary bladder cancer	0.000951	0.00271	CbGeAlD
Ruxolitinib—MAP3K3—vagina—urinary bladder cancer	0.00095	0.00271	CbGeAlD
Ruxolitinib—CLK2—lymph node—urinary bladder cancer	0.000942	0.00268	CbGeAlD
Ruxolitinib—Pancytopenia—Etoposide—urinary bladder cancer	0.000934	0.00545	CcSEcCtD
Ruxolitinib—Haemoglobin—Gemcitabine—urinary bladder cancer	0.000926	0.00541	CcSEcCtD
Ruxolitinib—Haemorrhage—Gemcitabine—urinary bladder cancer	0.000922	0.00538	CcSEcCtD
Ruxolitinib—Neutropenia—Etoposide—urinary bladder cancer	0.000919	0.00537	CcSEcCtD
Ruxolitinib—Bone pain—Epirubicin—urinary bladder cancer	0.000917	0.00535	CcSEcCtD
Ruxolitinib—Haemoglobin—Fluorouracil—urinary bladder cancer	0.000911	0.00532	CcSEcCtD
Ruxolitinib—Haemorrhage—Fluorouracil—urinary bladder cancer	0.000906	0.00529	CcSEcCtD
Ruxolitinib—DYRK1A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000906	0.0671	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000906	0.0671	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Valrubicin—urinary bladder cancer	0.000906	0.0671	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Valrubicin—urinary bladder cancer	0.000906	0.0671	CbGdCrCtD
Ruxolitinib—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.000905	0.00528	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—urinary bladder cancer	0.00089	0.00254	CbGeAlD
Ruxolitinib—BMPR2—lymph node—urinary bladder cancer	0.000887	0.00253	CbGeAlD
Ruxolitinib—Anaemia—Thiotepa—urinary bladder cancer	0.000881	0.00515	CcSEcCtD
Ruxolitinib—Infestation NOS—Etoposide—urinary bladder cancer	0.000877	0.00512	CcSEcCtD
Ruxolitinib—Infestation—Etoposide—urinary bladder cancer	0.000877	0.00512	CcSEcCtD
Ruxolitinib—TAOK3—vagina—urinary bladder cancer	0.000866	0.00247	CbGeAlD
Ruxolitinib—Bone pain—Doxorubicin—urinary bladder cancer	0.000848	0.00495	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—urinary bladder cancer	0.000847	0.00241	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.000829	0.00484	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000806	0.00471	CcSEcCtD
Ruxolitinib—CAMK2G—lymph node—urinary bladder cancer	0.000794	0.00226	CbGeAlD
Ruxolitinib—BMP2K—lymph node—urinary bladder cancer	0.000794	0.00226	CbGeAlD
Ruxolitinib—LRRK2—lymph node—urinary bladder cancer	0.000786	0.00224	CbGeAlD
Ruxolitinib—Infection—Thiotepa—urinary bladder cancer	0.000773	0.00451	CcSEcCtD
Ruxolitinib—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000763	0.00446	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000762	0.00445	CcSEcCtD
Ruxolitinib—Skin disorder—Thiotepa—urinary bladder cancer	0.000756	0.00441	CcSEcCtD
Ruxolitinib—Malnutrition—Cisplatin—urinary bladder cancer	0.000748	0.00437	CcSEcCtD
Ruxolitinib—Anaemia—Gemcitabine—urinary bladder cancer	0.000742	0.00433	CcSEcCtD
Ruxolitinib—Flatulence—Cisplatin—urinary bladder cancer	0.000737	0.0043	CcSEcCtD
Ruxolitinib—Anaemia—Fluorouracil—urinary bladder cancer	0.000729	0.00426	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—urinary bladder cancer	0.000721	0.00205	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—urinary bladder cancer	0.000714	0.00203	CbGeAlD
Ruxolitinib—TYK2—lymph node—urinary bladder cancer	0.000701	0.002	CbGeAlD
Ruxolitinib—IRAK1—lymph node—urinary bladder cancer	0.000692	0.00197	CbGeAlD
Ruxolitinib—MKNK2—lymph node—urinary bladder cancer	0.000692	0.00197	CbGeAlD
Ruxolitinib—Anaemia—Cisplatin—urinary bladder cancer	0.000691	0.00403	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000678	0.00396	CcSEcCtD
Ruxolitinib—RET—lymph node—urinary bladder cancer	0.000675	0.00192	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000672	0.00392	CcSEcCtD
Ruxolitinib—Fatigue—Thiotepa—urinary bladder cancer	0.000671	0.00392	CcSEcCtD
Ruxolitinib—Infection—Gemcitabine—urinary bladder cancer	0.00065	0.0038	CcSEcCtD
Ruxolitinib—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000642	0.00375	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000641	0.00374	CcSEcCtD
Ruxolitinib—Infection—Fluorouracil—urinary bladder cancer	0.00064	0.00373	CcSEcCtD
Ruxolitinib—JAK2—lymph node—urinary bladder cancer	0.000638	0.00182	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.000638	0.00372	CcSEcCtD
Ruxolitinib—Skin disorder—Gemcitabine—urinary bladder cancer	0.000636	0.00371	CcSEcCtD
Ruxolitinib—Anaemia—Etoposide—urinary bladder cancer	0.000633	0.0037	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000632	0.00369	CcSEcCtD
Ruxolitinib—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000631	0.00369	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00063	0.00368	CcSEcCtD
Ruxolitinib—PLK1—Idarubicin—Valrubicin—urinary bladder cancer	0.000619	0.0458	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Valrubicin—urinary bladder cancer	0.000619	0.0458	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Valrubicin—urinary bladder cancer	0.000619	0.0458	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000619	0.0458	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Valrubicin—urinary bladder cancer	0.000619	0.0458	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Valrubicin—urinary bladder cancer	0.000619	0.0458	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Valrubicin—urinary bladder cancer	0.000619	0.0458	CbGdCrCtD
Ruxolitinib—Body temperature increased—Thiotepa—urinary bladder cancer	0.000615	0.00359	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—urinary bladder cancer	0.000615	0.00175	CbGeAlD
Ruxolitinib—Infection—Cisplatin—urinary bladder cancer	0.000606	0.00354	CcSEcCtD
Ruxolitinib—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000598	0.00349	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000598	0.00349	CcSEcCtD
Ruxolitinib—Skin disorder—Cisplatin—urinary bladder cancer	0.000593	0.00346	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.00059	0.00344	CcSEcCtD
Ruxolitinib—CAMK2G—Azacitidine—Gemcitabine—urinary bladder cancer	0.000587	0.0435	CbGdCrCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000579	0.00338	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000565	0.0033	CcSEcCtD
Ruxolitinib—Fatigue—Gemcitabine—urinary bladder cancer	0.000565	0.0033	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000562	0.00328	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—urinary bladder cancer	0.00056	0.0016	CbGeAlD
Ruxolitinib—Pancytopenia—Methotrexate—urinary bladder cancer	0.000559	0.00326	CcSEcCtD
Ruxolitinib—Asthenia—Thiotepa—urinary bladder cancer	0.000558	0.00326	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000556	0.00324	CcSEcCtD
Ruxolitinib—Infection—Etoposide—urinary bladder cancer	0.000555	0.00324	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—urinary bladder cancer	0.000551	0.00321	CcSEcCtD
Ruxolitinib—Pruritus—Thiotepa—urinary bladder cancer	0.000551	0.00321	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000547	0.0032	CcSEcCtD
Ruxolitinib—Skin disorder—Etoposide—urinary bladder cancer	0.000543	0.00317	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000527	0.00308	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—urinary bladder cancer	0.000525	0.00307	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—urinary bladder cancer	0.000525	0.00307	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—urinary bladder cancer	0.000523	0.00306	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00052	0.00304	CcSEcCtD
Ruxolitinib—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000518	0.00302	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—urinary bladder cancer	0.000515	0.00301	CcSEcCtD
Ruxolitinib—Dizziness—Thiotepa—urinary bladder cancer	0.000515	0.003	CcSEcCtD
Ruxolitinib—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000509	0.00297	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—urinary bladder cancer	0.000502	0.00293	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—urinary bladder cancer	0.000501	0.00292	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—urinary bladder cancer	0.000499	0.00291	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000497	0.0029	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—urinary bladder cancer	0.000495	0.00289	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—urinary bladder cancer	0.000491	0.00287	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—urinary bladder cancer	0.000491	0.00287	CcSEcCtD
Ruxolitinib—Headache—Thiotepa—urinary bladder cancer	0.000488	0.00285	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000484	0.00283	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000483	0.00282	CcSEcCtD
Ruxolitinib—Body temperature increased—Cisplatin—urinary bladder cancer	0.000482	0.00282	CcSEcCtD
Ruxolitinib—Fatigue—Etoposide—urinary bladder cancer	0.000482	0.00281	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000478	0.00279	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—urinary bladder cancer	0.000477	0.00278	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—urinary bladder cancer	0.000474	0.00277	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—urinary bladder cancer	0.000471	0.00275	CcSEcCtD
Ruxolitinib—Asthenia—Gemcitabine—urinary bladder cancer	0.00047	0.00274	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—urinary bladder cancer	0.000469	0.00274	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000465	0.00271	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—urinary bladder cancer	0.000464	0.00271	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—urinary bladder cancer	0.000463	0.00271	CcSEcCtD
Ruxolitinib—Pruritus—Gemcitabine—urinary bladder cancer	0.000463	0.0027	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—urinary bladder cancer	0.000461	0.00269	CcSEcCtD
Ruxolitinib—Pruritus—Fluorouracil—urinary bladder cancer	0.000455	0.00266	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—urinary bladder cancer	0.000455	0.00265	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000455	0.00265	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—urinary bladder cancer	0.000443	0.00259	CcSEcCtD
Ruxolitinib—Body temperature increased—Etoposide—urinary bladder cancer	0.000442	0.00258	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000442	0.00258	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—urinary bladder cancer	0.000441	0.00258	CcSEcCtD
Ruxolitinib—Asthenia—Cisplatin—urinary bladder cancer	0.000438	0.00256	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—urinary bladder cancer	0.000434	0.00253	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00043	0.00251	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—urinary bladder cancer	0.000429	0.0025	CcSEcCtD
Ruxolitinib—Dizziness—Fluorouracil—urinary bladder cancer	0.000426	0.00249	CcSEcCtD
Ruxolitinib—PLK4—Teniposide—Etoposide—urinary bladder cancer	0.000413	0.0306	CbGdCrCtD
Ruxolitinib—PLK1—Teniposide—Etoposide—urinary bladder cancer	0.000413	0.0306	CbGdCrCtD
Ruxolitinib—Malnutrition—Methotrexate—urinary bladder cancer	0.00041	0.0024	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00041	0.00239	CcSEcCtD
Ruxolitinib—Headache—Gemcitabine—urinary bladder cancer	0.00041	0.00239	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000408	0.00238	CcSEcCtD
Ruxolitinib—Headache—Fluorouracil—urinary bladder cancer	0.000403	0.00235	CcSEcCtD
Ruxolitinib—Asthenia—Etoposide—urinary bladder cancer	0.000401	0.00234	CcSEcCtD
Ruxolitinib—Pruritus—Etoposide—urinary bladder cancer	0.000396	0.00231	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—urinary bladder cancer	0.000384	0.00224	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—urinary bladder cancer	0.000379	0.00221	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—urinary bladder cancer	0.000378	0.00221	CcSEcCtD
Ruxolitinib—Dizziness—Etoposide—urinary bladder cancer	0.00037	0.00216	CcSEcCtD
Ruxolitinib—CYP3A4—renal system—urinary bladder cancer	0.000363	0.00104	CbGeAlD
Ruxolitinib—Malnutrition—Doxorubicin—urinary bladder cancer	0.000355	0.00207	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—urinary bladder cancer	0.000355	0.00207	CcSEcCtD
Ruxolitinib—Headache—Etoposide—urinary bladder cancer	0.00035	0.00204	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—urinary bladder cancer	0.00035	0.00204	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000347	0.00203	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—urinary bladder cancer	0.000333	0.00194	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000328	0.00192	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—urinary bladder cancer	0.000328	0.00192	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000328	0.00191	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—urinary bladder cancer	0.000325	0.0019	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000325	0.0019	CcSEcCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—urinary bladder cancer	0.000315	0.0234	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—urinary bladder cancer	0.000315	0.0234	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—urinary bladder cancer	0.000315	0.0234	CbGdCrCtD
Ruxolitinib—Infection—Epirubicin—urinary bladder cancer	0.000311	0.00182	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000307	0.00179	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000307	0.00179	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—urinary bladder cancer	0.000304	0.00178	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.0003	0.00175	CcSEcCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—urinary bladder cancer	0.000292	0.0216	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000292	0.0216	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—urinary bladder cancer	0.000292	0.0216	CbGdCrCtD
Ruxolitinib—CYP3A4—female reproductive system—urinary bladder cancer	0.000291	0.000829	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000289	0.00169	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—urinary bladder cancer	0.000289	0.00169	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—urinary bladder cancer	0.000288	0.00168	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000284	0.00166	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000284	0.00166	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—urinary bladder cancer	0.000282	0.00164	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000271	0.00158	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—urinary bladder cancer	0.00027	0.00158	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—urinary bladder cancer	0.000265	0.00155	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00025	0.00146	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—urinary bladder cancer	0.00025	0.00146	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—urinary bladder cancer	0.000248	0.00145	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—urinary bladder cancer	0.00024	0.0014	CcSEcCtD
Ruxolitinib—Pruritus—Methotrexate—urinary bladder cancer	0.000237	0.00138	CcSEcCtD
Ruxolitinib—PLK1—Cytarabine—Gemcitabine—urinary bladder cancer	0.000232	0.0172	CbGdCrCtD
Ruxolitinib—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000229	0.00134	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—urinary bladder cancer	0.000225	0.00131	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—urinary bladder cancer	0.000222	0.00129	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—urinary bladder cancer	0.000221	0.00129	CcSEcCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—urinary bladder cancer	0.000215	0.016	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—urinary bladder cancer	0.000215	0.016	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—urinary bladder cancer	0.000215	0.016	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—urinary bladder cancer	0.000215	0.016	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—urinary bladder cancer	0.000215	0.016	CbGdCrCtD
Ruxolitinib—Headache—Methotrexate—urinary bladder cancer	0.00021	0.00122	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—urinary bladder cancer	0.000208	0.00121	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—urinary bladder cancer	0.000207	0.00121	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—urinary bladder cancer	0.000205	0.0012	CcSEcCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000199	0.0148	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—urinary bladder cancer	0.000199	0.0148	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—urinary bladder cancer	0.000199	0.0148	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—urinary bladder cancer	0.000199	0.0148	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—urinary bladder cancer	0.000199	0.0148	CbGdCrCtD
Ruxolitinib—Headache—Epirubicin—urinary bladder cancer	0.000196	0.00115	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—urinary bladder cancer	0.000192	0.00112	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—urinary bladder cancer	0.000182	0.00106	CcSEcCtD
Ruxolitinib—PRKCE—Signaling Pathways—EP300—urinary bladder cancer	1.21e-05	2.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—urinary bladder cancer	1.2e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.19e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—KRAS—urinary bladder cancer	1.19e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ERBB2—urinary bladder cancer	1.19e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CXCL8—urinary bladder cancer	1.19e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—KRAS—urinary bladder cancer	1.19e-05	2.55e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—urinary bladder cancer	1.18e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—urinary bladder cancer	1.18e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TERT—urinary bladder cancer	1.18e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—urinary bladder cancer	1.17e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—KRAS—urinary bladder cancer	1.17e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—SRC—urinary bladder cancer	1.17e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—urinary bladder cancer	1.17e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—KRAS—urinary bladder cancer	1.16e-05	2.51e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—RHOA—urinary bladder cancer	1.16e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—S100B—urinary bladder cancer	1.16e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—urinary bladder cancer	1.15e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FGFR3—urinary bladder cancer	1.15e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2—urinary bladder cancer	1.15e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—RHOA—urinary bladder cancer	1.14e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—urinary bladder cancer	1.14e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—urinary bladder cancer	1.14e-05	2.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB2—urinary bladder cancer	1.13e-05	2.44e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2—urinary bladder cancer	1.13e-05	2.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ESR1—urinary bladder cancer	1.12e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FGFR3—urinary bladder cancer	1.11e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2—urinary bladder cancer	1.11e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CREBBP—urinary bladder cancer	1.11e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—urinary bladder cancer	1.11e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—urinary bladder cancer	1.11e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCND1—urinary bladder cancer	1.11e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDH1—urinary bladder cancer	1.1e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—RHOA—urinary bladder cancer	1.1e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—urinary bladder cancer	1.09e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KRAS—urinary bladder cancer	1.09e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MYC—urinary bladder cancer	1.09e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ESR1—urinary bladder cancer	1.08e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CDKN1A—urinary bladder cancer	1.08e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGFR3—urinary bladder cancer	1.08e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2—urinary bladder cancer	1.08e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PTEN—urinary bladder cancer	1.08e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—urinary bladder cancer	1.08e-05	2.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB2—urinary bladder cancer	1.08e-05	2.32e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.07e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP9—urinary bladder cancer	1.07e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.07e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PTEN—urinary bladder cancer	1.07e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—urinary bladder cancer	1.07e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.06e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB2—urinary bladder cancer	1.06e-05	2.28e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MYC—urinary bladder cancer	1.05e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CDKN1A—urinary bladder cancer	1.05e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ESR1—urinary bladder cancer	1.05e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PTEN—urinary bladder cancer	1.05e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—urinary bladder cancer	1.05e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NCOR1—urinary bladder cancer	1.04e-05	2.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—urinary bladder cancer	1.03e-05	2.23e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EP300—urinary bladder cancer	1.03e-05	2.22e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—urinary bladder cancer	1.03e-05	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CREBBP—urinary bladder cancer	1.03e-05	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL8—urinary bladder cancer	1.02e-05	2.2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CDKN1A—urinary bladder cancer	1.02e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EP300—urinary bladder cancer	1.02e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2—urinary bladder cancer	1.02e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PTEN—urinary bladder cancer	1.02e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.01e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—urinary bladder cancer	1.01e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—urinary bladder cancer	1.01e-05	2.17e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—urinary bladder cancer	1.01e-05	2.17e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL8—urinary bladder cancer	1e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—SRC—urinary bladder cancer	1e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EP300—urinary bladder cancer	9.99e-06	2.15e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—urinary bladder cancer	9.97e-06	2.15e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—SRC—urinary bladder cancer	9.89e-06	2.13e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	9.89e-06	2.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—urinary bladder cancer	9.89e-06	2.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CREBBP—urinary bladder cancer	9.77e-06	2.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—urinary bladder cancer	9.75e-06	2.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—SRC—urinary bladder cancer	9.72e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—urinary bladder cancer	9.71e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CDKN1A—urinary bladder cancer	9.7e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EP300—urinary bladder cancer	9.69e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTEN—urinary bladder cancer	9.68e-06	2.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL8—urinary bladder cancer	9.67e-06	2.08e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1—urinary bladder cancer	9.65e-06	2.08e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—urinary bladder cancer	9.59e-06	2.07e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—urinary bladder cancer	9.51e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CREBBP—urinary bladder cancer	9.49e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—SRC—urinary bladder cancer	9.43e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1—urinary bladder cancer	9.37e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—urinary bladder cancer	9.35e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—urinary bladder cancer	9.32e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—urinary bladder cancer	9.31e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—RHOA—urinary bladder cancer	9.29e-06	2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—urinary bladder cancer	9.27e-06	2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—urinary bladder cancer	9.24e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—urinary bladder cancer	9.23e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EP300—urinary bladder cancer	9.23e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TERT—urinary bladder cancer	9.2e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CREBBP—urinary bladder cancer	9.2e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDKN1A—urinary bladder cancer	9.2e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTEN—urinary bladder cancer	9.18e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1—urinary bladder cancer	9.09e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—urinary bladder cancer	9.08e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDKN1A—urinary bladder cancer	9.05e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTEN—urinary bladder cancer	9.03e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SRC—urinary bladder cancer	8.97e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—urinary bladder cancer	8.9e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—urinary bladder cancer	8.87e-06	1.91e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RHOA—urinary bladder cancer	8.84e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—urinary bladder cancer	8.81e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—urinary bladder cancer	8.77e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EP300—urinary bladder cancer	8.75e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—urinary bladder cancer	8.67e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—urinary bladder cancer	8.63e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EP300—urinary bladder cancer	8.61e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—urinary bladder cancer	8.6e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RHOA—urinary bladder cancer	8.58e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—urinary bladder cancer	8.55e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—urinary bladder cancer	8.52e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SRC—urinary bladder cancer	8.51e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGFR3—urinary bladder cancer	8.45e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—urinary bladder cancer	8.44e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—urinary bladder cancer	8.41e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SRC—urinary bladder cancer	8.37e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RHOA—urinary bladder cancer	8.32e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—urinary bladder cancer	8.29e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—urinary bladder cancer	8.26e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—urinary bladder cancer	8.25e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ESR1—urinary bladder cancer	8.2e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—urinary bladder cancer	8.19e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—urinary bladder cancer	8.18e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—urinary bladder cancer	8.05e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—urinary bladder cancer	8.04e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1A—urinary bladder cancer	7.96e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—urinary bladder cancer	7.95e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—urinary bladder cancer	7.94e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMP—urinary bladder cancer	7.9e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—urinary bladder cancer	7.86e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—urinary bladder cancer	7.8e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—urinary bladder cancer	7.76e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—urinary bladder cancer	7.71e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—urinary bladder cancer	7.63e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EP300—urinary bladder cancer	7.57e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—urinary bladder cancer	7.53e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—urinary bladder cancer	7.5e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—urinary bladder cancer	7.49e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—urinary bladder cancer	7.46e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—urinary bladder cancer	7.43e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—urinary bladder cancer	7.42e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SRC—urinary bladder cancer	7.37e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1A—urinary bladder cancer	7.35e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—urinary bladder cancer	7.34e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—urinary bladder cancer	7.33e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—urinary bladder cancer	7.31e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—urinary bladder cancer	7.28e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—urinary bladder cancer	7.23e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—urinary bladder cancer	7.2e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CREBBP—urinary bladder cancer	7.19e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	7.15e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—urinary bladder cancer	7.1e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—urinary bladder cancer	7.07e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—urinary bladder cancer	7.05e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—urinary bladder cancer	7.05e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—urinary bladder cancer	7.02e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—urinary bladder cancer	7.02e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1A—urinary bladder cancer	7e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EP300—urinary bladder cancer	6.99e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—urinary bladder cancer	6.98e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—urinary bladder cancer	6.98e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—urinary bladder cancer	6.96e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—urinary bladder cancer	6.93e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—urinary bladder cancer	6.84e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—urinary bladder cancer	6.82e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—urinary bladder cancer	6.81e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SRC—urinary bladder cancer	6.8e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.79e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—urinary bladder cancer	6.78e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—urinary bladder cancer	6.67e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EP300—urinary bladder cancer	6.66e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—urinary bladder cancer	6.63e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—urinary bladder cancer	6.61e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1A—urinary bladder cancer	6.59e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—urinary bladder cancer	6.57e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RHOA—urinary bladder cancer	6.5e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SRC—urinary bladder cancer	6.47e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EP300—urinary bladder cancer	6.46e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—urinary bladder cancer	6.46e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—urinary bladder cancer	6.31e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SRC—urinary bladder cancer	6.28e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EP300—urinary bladder cancer	6.27e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—urinary bladder cancer	6.26e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.17e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—urinary bladder cancer	6.16e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—urinary bladder cancer	6.1e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SRC—urinary bladder cancer	6.09e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—urinary bladder cancer	6.09e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—urinary bladder cancer	6.02e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—urinary bladder cancer	5.99e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—urinary bladder cancer	5.96e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—urinary bladder cancer	5.89e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—urinary bladder cancer	5.8e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	5.71e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	5.71e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—urinary bladder cancer	5.71e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—urinary bladder cancer	5.67e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—urinary bladder cancer	5.67e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—urinary bladder cancer	5.63e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—urinary bladder cancer	5.63e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	5.54e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—urinary bladder cancer	5.51e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—urinary bladder cancer	5.46e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—urinary bladder cancer	5.46e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—urinary bladder cancer	5.36e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—urinary bladder cancer	5.34e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—urinary bladder cancer	5.32e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—urinary bladder cancer	5.2e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—urinary bladder cancer	5.18e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—urinary bladder cancer	5.16e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.15e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—urinary bladder cancer	5.13e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—urinary bladder cancer	5.05e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EP300—urinary bladder cancer	4.9e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—urinary bladder cancer	4.79e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—urinary bladder cancer	4.76e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SRC—urinary bladder cancer	4.76e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—urinary bladder cancer	4.62e-06	9.96e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	4.61e-06	9.92e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—urinary bladder cancer	4.56e-06	9.81e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—urinary bladder cancer	4.48e-06	9.66e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—urinary bladder cancer	4.42e-06	9.53e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—urinary bladder cancer	4.29e-06	9.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—urinary bladder cancer	4.27e-06	9.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—urinary bladder cancer	4.17e-06	8.99e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—urinary bladder cancer	3.94e-06	8.49e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.84e-06	8.28e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.57e-06	7.69e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.53e-06	7.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.53e-06	7.6e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—urinary bladder cancer	3.5e-06	7.55e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.38e-06	7.28e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—urinary bladder cancer	3.35e-06	7.22e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.32e-06	7.15e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.12e-06	6.72e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.53e-06	5.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.43e-06	5.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.99e-06	4.29e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.74e-06	3.74e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.66e-06	3.57e-06	CbGpPWpGaD
